Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180

Anti-Cancer Drugs

Volumn 24, Issue 9, 2013, Pages 945-957

  Lin, Yuli ^a   Yang, Xuguang ^a   Lu, Min ^a   Zheng, Weijuan ^a   Zhang, Jing ^a   Zhuang, Hongqin ^a,b   Hua, Zi Chun ^a,b  

^a NANJING UNIVERSITY   (China)

^b Jiangsu TargetPharma Laboratories Inc   (China)

Author keywords

apoptosis; cell cycle; synergism; triptolide; vasostatin120 180; xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CD31 ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 3; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; TRIPTOLIDE; UNCLASSIFIED DRUG; VASOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; TRIPTERYGIUM WILFORDII; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CALRETICULIN; CELL LINE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DITERPENES; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; EPOXY COMPOUNDS; ETHNOPHARMACOLOGY; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHENANTHRENES; RANDOM ALLOCATION; RECOMBINANT PROTEINS; TRIPTERYGIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883354398     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283651862     Document Type: Article

References (49)

1. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127:679-695.
5. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003; 27:405-411.
6. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
7. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13:159-167.
8. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90:1-7.
9. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998; 188:2349-2356.
10. Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, et al. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 2005; 11:28-35.
11. Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999; 94:2461-2468.
12. Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 2002; 51:358-366.
13. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 2007; 68:732-766.
14. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011; 11:377-383.
15. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108:630-637.
16. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett 1998; 133:169-175.
17. Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997; 112:113-117.
18. Lu LH, Lian YY, He GY, Lin SP, Huan SH, Chen ZZ. Clinical study of triptolide in treatment of acute leukemia. Clin Exp Investig Hematol 1992; 3:1-3.
19. Huynh PN, Hikim AP,Wang C, Stefonovic K, Lue YH, Leung A, et al. Longterm effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J Androl 2000; 21:689-699.
20. Ye X, Li W, Yan Y, Mao C, Cai R, Xu H, et al. Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 2010; 192:212-220.
21. Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003; 2:855-862.
22. Sun QM, Chen LL, Cao L, Fang L, Chen C, Hua ZC. An improved strategy for high-level production of human vasostatin120-180. Biotechnol Prog 2005; 21:1048-1052.
23. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681.
24. Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 2002; 34:462-468.
25. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
26. Fahy B, Bold RJ. Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 1998; 7:115-123.
27. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011; 8:39-47.
28. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117:2807-2812.
29. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58:17-38.
30. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96:5728-5733.
31. Sacco MG, Cato EM, Ceruti R, Soldati S, Indraccolo S, Caniatti M, et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther 2001; 8:67-70.
32. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-188.
33. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
34. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 2007; 28:87-114.
35. Xiao F,Wei Y, Yang L, Zhao X, Tian L, Ding Z, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002; 9: 1207-1213.
36. Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. J Pharmacol Exp Ther 1995; 272: 1305-1312.
37. Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der BD, van DL, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45: 1764-1772.
38. Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, et al. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res 2007; 13:4891-4899.
39. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999; 274:13451-13455.
40. Chang WT, Kang JJ, Lee KY,Wei K, Anderson E, Gotmare S, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276:2221-2227.
41. Zhu W, He S, Li Y, Qiu P, Shu M, Ou Y, et al. Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol 2010; 52:46-54.
42. Yang M, Huang J, Pan HZ, Jin J. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NFkappaB pathways in human multiple myeloma cells. Int J Mol Med 2008; 22:489-496.
43. Kang DW, Lee JY, Oh DH, Park SY, Woo TM, Kim MK, et al. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med 2009; 41:678-685.
44. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett 2010; 332:304-312.
45. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7:532-542.
46. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25:4812-4830.
47. Freedman DA,Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96-107.
48. Jiang XH,Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factorkappaB activation in gastric cancer cells. Oncogene 2001; 20:8009-8018.
49. Zhao F, Chen Y, Li R, Liu Y,Wen L, Zhang C. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspasedependent apoptosis in multiple myeloma in vitro. Toxicology 2010; 267:70-79.